Novel enzyme-free immunomagnetic microfluidic device based on Co 0.25 Zn 0.75 Fe 2 O 4 for cancer biomarker detection

• Published in: Analytica chimica acta 2019-09, Vol.1071, p.59
• Main Authors: Proença, Camila A, Baldo, Thaísa A, Freitas, Tayane A, Materón, Elsa M, Wong, Ademar, Durán, Andrés A, Melendez, Matias E, Zambrano, Gustavo, Faria, Ronaldo C
• Format: Article
• Language: English
• ISSN: 1873-4324

Early diagnosis of cancer by biomarker detection has been widely studied since it can lead to an increase in patient survival rates. Magnetic nanoparticles (MNPs) play an important role in this field acting as a valuable tool in the biomarker immunocapture and detection. In this work, Co Zn Fe O (CoZnFeONPs) nanoparticles were synthesized and applied as enzyme mimics of peroxidase-like catalysis in a disposable enzyme-free microfluidic immunoarray device (μID). The catalytic activity of CoZnFeONPs was evaluated by hydrogen peroxide detection using cyclic voltammetry and the apparent Michaelis-Menten constant was estimated by Lineweaver-Burk equation showing good K values. In μID, the immunosensors were assembled with monoclonal antibody against CYFRA 21-1 covalently immobilized on graphene oxide previously deposited on the screen-printed carbon-based electrodes. Under optimized conditions, the method presented a good linear response for CYFRA 21-1 in the range of 3.9-1000 fg mL achieving an ultralow limit of detection (LOD) of 0.19 fg mL . For comparison, Fe O nanoparticles (FeONPs) was also synthetized and presented results slight inferior to that obtained with CoZnFeONPs. The methods developed using both MNPs exhibited countless advantages when compared with the immunosensors developed for CYFRA-21-1, previously reported in the literature. The methods were successful applied for the detection of CYFRA 21-1 in real serum samples of healthy and prostate cancer patients and showed good correlation with results obtained with the enzyme-linked immunosorbent assay (ELISA). The CoZnFeONPs associated with the disposable microfluidic immunoarray device provides a simple and effective method for biomarker detection that could satisfy the need for a low-cost and rapid test for early diagnosis of cancer.